Hikal Reports Q2 FY27 Revenue Growth of 36% YoY With Stronger Operating Margins
Hikal Ltd · Investor Presentation · 03 Nov 2026, 9:39 pm
Hikal Reports Q2 FY27 Revenue Growth of 36% YoY With Stronger Operating Margins Hikal reported consolidated revenue of ₹434 crore for Q2 FY27, up 36% YoY, driven by a 47% YoY growth in Pharmaceuticals to ₹278 crore and a 21% YoY rise in Crop Protection to ₹156 crore. EBITDA surged 524% YoY to ₹45 crore, expanding margins by 808 bps YoY to 10.3%. Net loss narrowed to ₹6 crore from ₹35 crore in Q2 FY26. For H1 FY27, revenue rose 20% YoY to ₹837 crore, while EBITDA reached ₹82 crore. Management reiterated full-year guidance of mid-teens revenue growth and substantial profitability improvement.
Original exchange filing (PDF)
More announcements from Hikal Ltd
- Transcript of Earnings Call for the Quarter and half year ended September 30, 2026. · 05 Nov 2026
- Audio Recording of Group Conference call for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Announcement under Regulation 30 of SEBI LODR 2015- Press Release on the results of the Company for the quarter and half year ended September 30, 2026. · 03 Nov 2026
- Pursuant to Regulation 30(5) of the SEBI LODR Regulations- List of KMP authorized to determine materiality and make disclosures. · 03 Nov 2026
- Unaudited Financial Results for the quarter and half year ended September 30, 2026 · 03 Nov 2026
- Hikal Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 03 Nov 2026
- Unaudited Financial Results for the quarter and half year ended September 30, 2026 · 03 Nov 2026
- Press Release on Hikal signs Multi-Year Global CDMO contract with leading Agrochemical Company · 02 Nov 2026
